Reversal of advanced diabetic kidney disease in mice treated with a monoclonal anti-VEGFR1 antibody
Kidney International · 2026
DOI: 10.1016/j.kint.2026.03.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2026. Verfasst von Zhonghua Qi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Lilly Research Laboratory, Eli Lilly and Company, Indianapolis, Indiana, USA. Electronic address: Qi_zhonghua@lilly.com. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Vascular Endothelial Growth Factor Receptor-1, Antibodies, Monoclonal, Kidney. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kasturba Medical College, Manipal.
Abstract (Originalsprache)
INTRODUCTION: Diabetic kidney disease (DKD) continues to be the major cause of kidney failure, and its treatment is of key importance. Targeting VEGF-A has yielded conflicting results in DKD models. Here, we investigated the potential benefit of targeting VEGF-A or its receptors for the treatment of advanced mouse DKD. METHODS: Our studies tested the effects of neutralizing antibodies targeting VEGF-A, VEGFR2, and VEGFR1 on kidney function and histopathology, in 4 different mouse models of DKD and chronic kidney disease (CKD). RESULTS: Unlike previous reports, blocking VEGF-A using an anti-VEGF-A monoclonal antibody worsened albuminuria and kidney injury in uninephrectomized (unix) diabetic db/db mice. Similar results were seen with the anti-VEGFR2 antibody (DC101). In contrast, antibody MF1, a VEGFR1 selective monoclonal blocking antibody, dramatically decreased albuminuria, improved kidney function, and reduced renal histological injury in the remnant kidney mice, unix db/db mice with or without renin-AAV injection, and eNOS-/-db/db hypertensive mice. MF1 also improved animal survival. MF1 benefit persisted in albuminuric transgenic mice lacking the VEGFR1 cytoplasmic tyrosine kinase domain. In renin-AAV unix db/db mice with advanced DKD, we observed improved survival, reduced serum creatinine, and regression of established kidney histological changes following delayed MF1 treatment. VEGFR1 antibody increased circulating placental growth factor and VEGF-A as well as phosphorylation of kidney VEGFR2. MF1 reduced blood pressure in diabetic eNOS-/- mice and acutely increased the glomerular filtration rate in db/db mice. CONCLUSIONS: Our studies demonstrate that blocking VEGFR1 improved kidney function and microvascular structure in models of progressive CKD. VEGFR1 blockade provided a promising novel therapeutic approach to reverse DKD progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lilly Research Laboratory, Eli Lilly and Company, Indianapolis, Indiana, USA. Electronic address: Qi_zhonghua@lilly.com.
- Lilly Research Laboratory, Eli Lilly and Company, Indianapolis, Indiana, USA.
- Department of Physiology and Neuroscience, University of Southern California, Los Angeles, California, USA.
- Pathology Associates, Charles River Laboratories, Frederick, Maryland, USA.
Förderung
- Kasturba Medical College, Manipal
Zitieren
APA
Qi, Z., Tang, Y., Croy, J. E., Wilson, J. M., Heinz-Taheny, K. M., Credille, K. M., Dey, A. B., Coskun, T., Ding, Y., Jaqua, D., Su, Y., Vitale, O. H., Hamang, M. J., Majumdar, A., Conner, E. M., Schiessl, I. M., Peti-Peterdi, J., Gyarmati, G., Raymond, J. T., …, & Breyer, M. D. (2026). Reversal of advanced diabetic kidney disease in mice treated with a monoclonal anti-VEGFR1 antibody. Kidney International. https://doi.org/10.1016/j.kint.2026.03.016
Vancouver
Qi Z, Tang Y, Croy JE, Wilson JM, Heinz-Taheny KM, Credille KM, et al. Reversal of advanced diabetic kidney disease in mice treated with a monoclonal anti-VEGFR1 antibody. Kidney International. 2026. doi:10.1016/j.kint.2026.03.016
BibTeX
@article{Qi2026,
author = {Qi, Zhonghua and Tang, Ying and Croy, Johnny Eugene and Wilson, Jonathan M and Heinz-Taheny, Kathleen M and Credille, Kelly M and Dey, Asim Bikash and Coskun, Tamer and Ding, Yan and Jaqua, Dianna and Su, Yuan and Vitale, Olivia Hope and Hamang, Matthew J and Majumdar, Arindam and Conner, Elaine M and Schiessl, Ina Maria and Peti-Peterdi, Janos and Gyarmati, Georgina and Raymond, James T and Duffin, Kevin L and Liu, Ling and Breyer, Matthew D},
title = {Reversal of advanced diabetic kidney disease in mice treated with a monoclonal anti-VEGFR1 antibody},
journal = {Kidney International},
year = {2026},
doi = {10.1016/j.kint.2026.03.016}
}
EUVIMED